Effects of Ranibizumab Combined with Pancreatic Kininogenase on Ocular Hemodynamics and Visual Acuity in Patients with Diabetic Retinopathy
Objective To analyze the impact of ranibizumab combined with pancreatic kininogenase on ocular hemodynamics and visual acuity in patients with diabetic retinopathy(DR).Methods This study selected 90 patients with DR admitted to Kaifeng Central Hospital from January 2020 to April 2023,all of whom underwent vitrectomy treatment.According to different treatment methods,they were divided into a control group and an experimental group,with 45 cases in each group.The control group was given ranibizumab,while the experimental group were given ranibizumab combined with pancreatic kininogenase.The clinical efficacy,eye-related indicators(best corrected visual acuity,macular foveal retinal thickness,visual field grayscale value),inflammatory indicators[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),soluble intercellular adhesion molecule-1(sICAM-1)],fundus hemodynamics[central retinal artery resistance index(RI),pulsatility index(PI),end diastolic velocity(EDV),peak velocity(PSV),mean velocity(MV)],and adverse reactions were compared between the two groups.Results The total effective rate of the experimental group was 88.89%,which was higher than that of the control group(71.11%)(P<0.05).After 3 months of continuous treatment,the experimental group showed better improvement in best corrected visual acuity,macular foveal retinal thickness,and visual field grayscale value than the control group(P<0.05);both groups showed a downward trend in serum IL-6,TNF-α,and sICAM-1 levels,with the experimental group showing a greater downward trend than the control group(P<0.05);both groups showed faster improvement in EDV,PSV,and MV than before treatment,and lower PI and RI than before treatment,with the experimental group showing better improvement than the control group(P<0.05).During the treatment period,the incidence of adverse reactions in the experimental group was 13.33%,which was not significantly different from that of the control group(8.89%)(P>0.05).Conclusion The combination of ranibizumab and pancreatic kininogenase is effective in treating DR,improving patients'vision,regulating ocular hemodynamics,inhibiting inflammatory reactions,and is safe and reliable.
NETL
NSTL
万方数据
